Comparison of Preventive Effect of RDS and Neonatal Morbidity between Antenatal Dexamethasone versus Ambroxol Administration.
- Author:
Eun Jeong KIM
1
;
Seong Sook JEON
;
Son Sang SEO
Author Information
1. Department of Pediatrics, Ilsin Christian Hospital, Pusan, Korea.
- Publication Type:Original Article
- Keywords:
Dexamethasone;
Ambroxol;
Respiratory distress syndrome (RDS)
- MeSH:
Ambroxol*;
Dexamethasone*;
Humans;
Incidence;
Infant;
Membranes;
Mothers;
Pregnancy;
Puerperal Infection;
Retrospective Studies;
Rupture;
Sepsis
- From:Journal of the Korean Pediatric Society
2000;43(1):13-22
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Antenatal dexamethasone administration is associated with a significant lowering respiratory distress syndrome (RDS) incidence, but can increase neonatal infection. Ambroxol has been accepted as an alternative treatment to dexamethasone and is of at least equal efficacy but without adverse reaction. The aim of this study was to evaluate the effectiveness of ambroxol versus dexamethasone in RDS incidence and neonatal infection. METHODS: In this study, 30 infants, who received prenatal dexamethasone therapy, were compared retrospectively to 19 infants who received prenatal ambroxol therapy and 45 infants who received placebo during 28 to 34 weeks' of gestation. RESULTS: RDS incidence was comparable in both the dexamethasone (10.0%) and ambroxol (10.5%) groups but higer in the control group (26.6%). The puerperal infection rate in the mothers of these infants was 33.3% in the dexamethasone group, 10.5% in the ambroxol group and 20.0% in the control group. Neonatal infection in the 28 days following delivery was 56.6% in the dexamethasone group, 26.3% in the ambroxol group and 26.6% in the control group. Neonatal infection rate of the dexamethasone group was higher than ambroxol and control groups (P<0.05). When premature rupture of membrane was controlled, the sepsis rate (<28 days) was significantly lower in the ambroxol group than in the dexamethasone group (P<0.05), but puerperal infection and sepsis (<7 days) were not significantly different. CONCLUSOIN: Ambroxol was as effective as the dexamethasone in reducing the RDS incidence. Neonatal and puerperal infection were significantly higher in the dexamethasone group than in the ambroxol group.
